Finite-time measurement-driven Otto cycle.

A novel quantum Otto heat engine that operates within a finite-time framework by incorporating measurement procedures is proposed. Departing from conventional quantum Otto heat engines, our model replaces the heat absorption process from a high-temperature source with invasive measurement. Moreover, we consider finite-time thermodynamic manipulation in each step.

Efficiency bounds for bipartite information-thermodynamic systems.

In this paper, we introduce an approach to derive a lower bound for the entropy production rate of a subsystem by utilizing the Cauchy-Schwarz inequality. It extends to establishing comprehensive upper and lower bounds for the efficiency of two subsystems. These bounds are applicable to a wide range of Markovian stochastic processes, which enhances the accuracy in depicting the range of energy conversion efficiency between subsystems.

Compact Radiative Divertor Experiments at ASDEX Upgrade and Their Consequences for a Reactor.

We present a novel concept to tackle the power exhaust challenge of a magnetically confined fusion plasma. It relies on the prior establishment of an X-point radiator that dissipates a large fraction of the exhaust power before it reaches the divertor targets. Despite the spatial proximity of the magnetic X point to the confinement region, this singularity is far away from the hot fusion plasma in magnetic coordinates and therefore allows the coexistence of a cold and dense plasma with a high potential to radiate.

Viral vectors as a novel tool for clinical and neuropsychiatric research applications.

Background: A viral vector is a genetically modified vector produced by genetic engineering. As pathogenic genes in the virus are completely or largely eliminated, it is safe to be widely used in multidisciplinary research fields for expressing genes, such as neuroscience, metabolism, oncology and so on. Neuroscience and psychiatry are the most closely related disciplines in either basic research or clinical research, but the application of viral vectors in neuropsychiatry has not received much attention or not been widely accepted.

Evaluation of recombinant monoclonal antibody SVmab1 binding to Na 1.7 target sequences and block of human Na 1.7 currents.

Identification of small and large molecule pain therapeutics that target the genetically validated voltage-gated sodium channel Na 1.7 is a challenging endeavor under vigorous pursuit. The monoclonal antibody SVmab1 was recently published to bind the Na 1.